by Raynovich Rod | Dec 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Crude Trade Roils Markets-But Biotech Is Still A Safe Haven Second Worst Week of the Year-Late Day Trading Hit By Selling As the market becomes more volatile we should look at how the energy trade is affecting other asset classes. Certainly materials and industrials...
by Raynovich Rod | Dec 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Bounce Back Day 12/2/14 FBT up 1.5% to $102.33 Biotech players realized that news about China, energy and holiday shopping data do not affect their stocks. Our large cap biopharma portfolio went green helped by Biogen Idec (BIIB) up 6.43% on Phase 1a data for an...
by Raynovich Rod | Nov 14, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Red Tape Today Means Caution-Take Some Off XBI at $167.83 Off 2% Traders, investors, executives even pension funds are thrilled with biotech investing as the stock group rolls on to new highs this month. What may not be appreciated is the 20% move off the October 16...
by Raynovich Rod | Oct 16, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
11/15/14 Speculative Small Cap Stocks-Stay Away Unless Your Are A Trader Nice profits were booked on our recent small cap picks but today the sell-off was “pronounced”: Celldex (CLDX) was down 21% to $13.10 after hitting a high near $18 on October 31....
by Raynovich Rod | Sep 24, 2014 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 …After 1.94% NASDAQ Sell-Off All three market indices got crushed today with a downdraft attributed to ending of QE, rising i rates in 2015, a rising dollar and just plain profit taking. A 3.8% hit on Apple (AAPL) did not help support the QQQ which also...
by Raynovich Rod | Aug 26, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Stocks- Including New Picks Another great day for biotech with most Rayno stocks in a rally mode with a bit of profit taking on Gilead Sciences(GILD) down 1%. Notable movers up on our core picks are: Alkermes (ALKS), Amgen (AMGN), Ariad (ARIA),...
by Raynovich Rod | Jul 29, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Some Huge Moves Today Brings Hope For Summer Rally ETFs Up: FBT $83 up 2.58%, IBB $254.78 up 1.14%, XBI $148.9 up 3.28%. Rayno Large Cap Portfolio: up 14,4% YTD with Biogen Idec(BIIB) and Gilead (GILD) leaders; near July highs. Virtually everything is up but big...
by Raynovich Rod | Jul 22, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out...
by Raynovich Rod | Jun 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014 on personalized medicine and...
by Raynovich Rod | Jun 26, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Challenges Ahead But Sequencing Is A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum...
